Procurement Summary
Country: USA
Summary: Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formular Additional Discount Program
Deadline: 18 Sep 2025
Other Information
Notice Type: Tender
TOT Ref.No.: 125591325
Document Ref. No.: HT9402-25-Q-9403
Financier: Self Financed
Purchaser Ownership: Public
Tender Value: Refer Document
Purchaser's Detail
Name: Login to see tender_details
Address: Login to see tender_details
Email: Login to see tender_details
Login to see detailsTender Details
Description
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: The following November 2025 drug classes/subclass or newly approved drugs will be reviewed:
a. Anzupgo - Atopy - Subclass: N/Ab. Brinsupri - Pulmonary-1 Agents - Subclass: N/Ac. Brynovin - Diabetes Non-Insulin - Subclass: DPP-4 Inhibitorsd. Ekterly - Corticosteroids-Immune Modulators - Subclass: Hereditary Angioedema Agentse. Harliku - Metabolic Agents-Miscellaneous - Subclass: Replacement Enzymesf. Hernexeos - Oncological Agents - Subclass: N/Ag. Kirsty - Insulins - Subclass: Rapid-Acting Agents U-100h. Lopressor - Beta Blockers and Hydrochlorothiazide Combinations - Subclass: N/Ai. Modeyso - Oncological Agents - Subclass: N/Aj. Orlynvah - Antibiotics - Subclass: Beta-lactamsk. Sephience - Metabolic Agents-Miscellaneous - Subclass: N/Abr...
Active Contract Opportunity
Notice ID : HT9402-25-Q-9403
Related Notice
Department/Ind. Agency : DEPT OF DEFENSE
Sub-tier : DEFENSE HEALTH AGENCY (DHA)
Office: DEFENSE HEALTH AGENCY
General Information
Contract Opportunity Type: Solicitation (Original)
Original Published Date: Sep 02, 2025 05:03 pm EDT
Original Date Offers Due: Sep 18, 2025 12:00 pm EDT
Inactive Policy: Manual
Original Inactive Date: Feb 28, 2026
Initiative: None
Classification
Original Set Aside:
Product Service Code: 6505 - DRUGS AND BIOLOGICALS
NAICS Code: 325412 - Pharmaceutical Preparation Manufacturing
Place of Performance: San Antonio, Tx 78230 USA
Documents
Tender Notice
RFQ-HT9402-25-Q-9403-NAD.pdf
Price-List-Anzupgo-Atopy-NA.xlsx
Price-List-Brinsupri-Pulmonary-1-Agents-NA.xlsx
Price-List-Brynovin-Diabetes-Non-Insulin-DPP.xlsx
Price-List-Ekterly-Corticosteroids-Immune-Modu.xlsx
Price-List-Harliku-Metabolic-Agents-Miscellane.xlsx
Price-List-Hernexeos-Oncological-Agents-NA.xlsx
Price-List-Kirsty-Insulins-Rapid-Acting-Agen.xlsx
Price-List-Lopressor-Beta-Blockers-and-Hydroch.xlsx
Price-List-Modeyso-Oncological-Agents-NA.xlsx
Price-List-Orlynvah-Antibiotics-Beta-lactams.xlsx
Price-List-Sephience-Metabolic-Agents-Miscella.xlsx
DoD-Formulary-Placement-of-FDA-Newly-Approved-Drug.pdf
Price-Appendix-FAQ-NAD.pdf